Once weekly treatment with epoetin-β

Nephrology Dialysis Transplantation

Volumn 20, Issue SUPPL. 6, 2005, Pages

  Locatelli, Francesco ^a,b  

^a A MANZONI HOSPITAL   (Italy)

^b Divisione di Nefrologia e Dialisi   (Italy)

Author keywords

Anaemia; Chronic kidney disease; Dosing frequency; Epoetin ; Haemoglobin

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; HEALTH PRACTITIONER; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERTENSION; NURSING; OUTPATIENT CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; SYRINGE; CHRONIC KIDNEY FAILURE; DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC;

EID: 32944461752     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh1095     Document Type: Article

References (21)

1. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
2. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178
3. Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1991; 1: 990-998
4. Koch KM, Koene RA, Messinger D, Quarder O, Scigalla P. The use of epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol 1995; 44: 201-208
5. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998; 13: 1642-1644
6. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619
7. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132
8. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10: 1309-1316
9. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78
10. Bommer J, Muller-Buhl E, Ritz E, Eifert J. Recombinant human erythropoietin in anaemic patients on haemodialysis. Lancet 1987; 1: 392
11. Bommer J, Kugel M, Schoeppe W et al. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol 1988; 66: 85-93
12. Granolleras C, Leskopf W, Shaldon S, Fourcade J. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: A randomized, double-blind crossover study. Clin Nephrol 1991; 36: 294-298
13. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578-583
14. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anaemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-446
15. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: Ii1-ii47
16. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37 [Suppl 1]: S182-S238
17. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: Results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 2000; 15: 2014-2019
18. Locatelli F, Baldamus C, Villa G, Ganea A, De Francisco AM. A rational for an individualized administration frequency of epoetin β: A pharmacological perspective. Nephrol Dial Transplant 2002; 17 [Suppl 6]: 13-16
19. Locatelli F, Baldamus CA, Villa G et al. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: Results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 2002; 40: 119-125
20. Grzeszczak W, Sulowicz W, Rutkowski B et al. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin β in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant 2005; 20: 936-944
21. Frifelt JJ, Tvedegaard E, Bruun K et al. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly. Perit Dial Int 1996; 16: 594-598